Latest Articlesddd

Exelixis initiates a phase 3 trial with cabozantinib combination for previously untreated liver cancer

December 6, 2018 0

Exelixis (EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) announced the initiation of COSMIC-312. A phase 3 pivotal trial of cabozantinib …

Amgen and UCB product for bone fracture in susceptible postmenopausal women. What about the Market’s deep dips?

December 6, 2018 0

Another reason was found to hit the market when the economy is good and sustained and …

Celgene has important CAR T presentations at ASH

December 4, 2018 0

At the 60th American Society of Hematology (ASH) Annual Meeting   CAR T is Still a Star With …

When common sense fails to explain market performance

December 3, 2018 0

Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual …

Why Celyad stock lost today instead of gaining on good news

November 30, 2018 0

Celyad (CYAD) is still a clinical-stage biopharmaceutical company developing advanced or improved CAR-T cell-based therapies. Today, …

Vertex: Offering proof of leadership in treating Cystic Fibrosis

November 29, 2018 0

Vertex Pharmaceuticals’ triple combination, which added the corrector VX-659 to the tezacaftor and ivacaftor combination, resulted …

Loxo Oncology product Vitrakvi® has been granted FDA approval. The real meaning of the approval

November 27, 2018 0

As we expected in our posting yesterday under Today’s Highlights, the U.S. Food and Drug Administration (FDA) …

RegenxBio attracts more companies. Why Loxo is important to observe today

November 26, 2018 0

We hope you all took advantage of the Thanksgiving holiday to rest and relax. We did. …

A great day for Exelixis

November 15, 2018 0

This is just to inform that Europe has approved Cabometyx® (cabozantinib) tablets as a monotherapy for hepatocellular …

What the Aimmune and Nestlé Health Science agreement tells us

November 14, 2018 0

Aimmune Therapeutics (AIMT) has news. A lot of it is from a successful phase 3 trial …

Improving on immunotherapy and preventing one of its serious side effects

November 13, 2018 0

The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. …

Excellent news about little known products and Nektar Therapeutics

November 12, 2018 0

The Week in Review, which we will post soon, is going to provide news that cancer …

Jazz Pharmaceuticals has good, not bad news

November 9, 2018 0

In today’s news Jazz Pharmaceuticals (JAZZ) announced the submission of a Marketing Authorization Application (MAA) to the European …

The molecule that enhanced the T Cells cancer treatment efficacy while preventing autoimmune diseases

November 8, 2018 0

Yesterday, the Stock Market skyrocketed and with it a significant number of Prohost Picks that we …

RegenxBio: Another licensing agreement providing additional validation of its NAV platform

November 5, 2018 0

RegenxBio (RGNX) has granted Abeona Therapeutics (ABEO) an exclusive worldwide license to its NAV AAV9 viral vector (subject …

About Illumina’s acquisition

November 2, 2018 0

Illumina (ILMN) and Pacific Biosciences (PACB) announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a …

About Exelixis

November 2, 2018 0

Exelixis (EXEL) provided an update that testified to its solid fundamentals, the growth of its approved …

About the Celyad/Horizon discovery agreement

November 1, 2018 0

Celyad (CYAD) announced an exclusive agreement with Horizon Discovery Group plc, for the use of its shRNA …

Observing Array Biopharma

October 31, 2018 0

A number of biotech or biopharmaceutical companies have succeeded in the past couple of years in …

We call it the bad market

October 30, 2018 0

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …